BenzingaT3·12mo ago
MIRA MIRA Pharmaceuticals, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MIRA
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 2
- List Date
- 2023-08-03
- CIK
- 0001904286
- Next Earnings
- 2026-11-12
- Headquarters
- Miami, FL
- Homepage
- https://www.mirapharmaceuticals.com
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | -21.01% | 4.35% | -16.78% | -11.15% |
| Feb | -- | 4.69% | -13.79% | 4.96% | -1.38% |
| Mar | -- | 5.78% | 7.70% | -17.05% | -1.19% |
| Apr | -- | -21.31% | 21.47% | -0.94% | -0.26% |
| May | -- | -0.13% | 18.42% | 1.92% | 6.74% |
| Jun | -- | -25.12% | -12.95% | -9.86% | -15.98% |
| Jul | -- | 218.66% | 36.36% | -15.18% | 79.95% |
| Aug | -15.45% | -20.58% | -11.04% | 25.46% | -5.40% |
| Sep | -24.76% | -27.78% | -2.86% | -1.77% | -14.29% |
| Oct | -58.46% | 84.03% | 26.52% | -26.31%* | 6.45% |
| Nov | 135.10% | -32.11% | -12.94% | -- | 30.02% |
| Dec | -72.37% | -20.28% | 7.86% | -- | -28.26% |
| Total | -82.83% | -6.29% | 69.84% | -49.21% | -17.12% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.69
SMA 50: $0.75
SMA 200: $0.98
Current: $0.53
EMA 12: $0.65
EMA 26: $0.70
MACD: -0.0500 | Signal: -0.0119
BEARISH
ADX (14): 24.64
WEAK TREND
+DI: 14.26
−DI: 33.89
Momentum Oscillators
RSI (14): 29.57
OVERSOLD
Stoch %K: 7.82
Stoch %D: 16.14
Williams %R: -93.94
Volume & Volatility
BB Upper: $0.84
BB Lower: $0.55
OVERSOLD
OBV: 266,598,644
Vol SMA 20: 127,955
Vol ROC: 167.21%
ATR: $0.06
True Range: $0.13
HV 20: 88.6%
HV 30: 91.1%
HV 60: 100.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: MIRA
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers: Positive news sentiment and recent acquisitions, offset by high volatility and moderate technical signals.
Primary Risks: High risk of price fluctuations due to high volatility, potential for earnings misses or negative surprises.
Investment Thesis: Mira Pharmaceuticals is a growth-oriented company with a strong pipeline of cannabinoid-based treatments. Recent acquisitions have expanded its capabilities, but high volatility and market uncertainty pose significant risks.
Recent News Sentiment Impact: Positive news headlines have driven recent price movements, but investors should remain cautious due to the company's high-risk profile.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): NEUTRAL
- Medium-term (1-3 months): BEARISH (SMA 50 and EMA 26 are below current price)
- Long-term (3-12 months): BULLISH (SMA 200 is above current price)
Support/Resistance Levels:
- Resistance: $0.99 (upper Bollinger Band) and $1.23 (SMA 200)
- Support: $0.89 (lower Bollinger Band) and $0.97 (SMA 50)
Momentum Signals:
- RSI interpretation: NEUTRAL (47.11, not overbought or oversold)
- MACD signal: BEARISH (histogram is negative)
- Bollinger Bands position: NEUTRAL (price is near the middle band)
Volume Analysis:
- Volume trend: INCREASING (volume SMA 20 is rising)
- Institutional interest signals: MIXED (OBV is positive, but volume rate of change is high)
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines have driven recent price movements, highlighting the company's growing pipeline and acquisitions.
Sentiment Assessment: POSITIVE (4/5, with most recent articles having a positive sentiment)
Catalyst Identification: Upcoming earnings announcements may provide additional catalysts for price movement.
Market Narrative: The market is likely to remain cautious due to high volatility and potential for earnings misses or negative surprises.
Risk & Volatility Assessment
Beta Interpretation: HIGH RISK (beta is 1.33, indicating a higher risk profile)
Volatility Regime: CURRENT (volatility is relatively high compared to historical levels)
Options Market Signals: IV PREMIUM IS POSITIVE (implied volatility is richer than realized)
Downside Protection: Support levels are at $0.89 (lower Bollinger Band) and $0.97 (SMA 50), with potential for a bounce.
Market Context & Positioning
Sector Performance: CANNABIS SECTOR IS STRONG, WITH MIRA PHARMACEUTICALS POSITIVELY CORRELATED (R-squared: 0.5)
Institutional Activity: MIXED INSTITUTIONAL INTEREST SIGNALS (OBV is positive, but volume rate of change is high)
Relative Valuation: MIRA PHARMACEUTICALS IS TRADING NEAR ITS HISTORICAL PEAK VALUE
Key Levels & Action Items
Critical Price Levels:
- Resistance: $0.99 and $1.23
- Support: $0.89 and $0.97
Breakout/Breakdown Levels: Watch for potential breakouts above the upper Bollinger Band or breakdowns below the lower Bollinger Band.
Time-Sensitive Catalysts: Upcoming earnings announcements may provide additional catalysts for price movement.
Risk Management: Consider stop-loss levels at $0.85 and position sizing considerations based on risk tolerance.
This comprehensive analysis provides a nuanced view of Mira Pharmaceuticals, highlighting both bullish and bearish arguments. Investors should carefully consider the company's high-risk profile, recent news sentiment, and technical signals before making investment decisions.
Generated
News
All MIRA news →
GlobeNewswire Inc.T3·14mo ago
BenzingaT3·17mo ago
GlobeNewswire Inc.T3·20mo ago
BenzingaT3·31mo ago
BenzingaT3·32mo ago
BenzingaT3·32mo ago
BenzingaT3·33mo ago
BenzingaT3·35mo ago
BenzingaT3·35mo ago
Showing 1–10 of 17
Page 1 of 2
MIRA Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.1021
Alpha: -91.72%
Correlation: 0.1931
R-Squared: 3.7%
Stock Volatility: 72.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own MIRA
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $18K | #6189 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MIRA Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
MIRA Insider Trading (Form 4)
Latest: 2026-06-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Denil Nanji Shekhat | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-06-15 | Matthew Paul Del Giudice | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-06-15 | Matthew Pratt Whalen | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-06-15 | Edward Clouston MacPherson | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-04-01 | Erez Aminov | Chief Executive Officer | Grant (A) | +83,500 RSU | — | EDGAR | |
| 2025-10-03 | Denil Nanji Shekhat | Director | Award (A) | +22,378 | $1.35 | $30.2K | EDGAR |
| 2025-10-03 | Erez Aminov | Chief Executive Officer | Award (A) | +2,685,456 | — | EDGAR | |
| 2025-09-18 | Erez Aminov | Chief Executive Officer | Grant (A) | +300,000 opt | — | EDGAR | |
| 2025-09-03 | Erez Aminov | Chief Executive Officer | Award (A) | +62,500 | $1.37 | $85.6K | EDGAR |
| 2024-12-10 | Matthew Paul Del Giudice | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2024-12-10 | Edward Clouston MacPherson | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2024-12-10 | Matthew Pratt Whalen | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2024-12-10 | Denil Nanji Shekhat | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2024-12-10 | Michelle Yanez | Chief Financial Officer | Grant (A) | +150,000 opt | — | EDGAR | |
| 2024-12-10 | Erez Aminov | Chief Executive Officer | Grant (A) | +2,500,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MIRA Insider Holdings
2 insiders · @ $0.53
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Erez Aminov | Chief Executive Officer | 3,530,156 | $1.88M | -$125.5K | 10 | 2026-04-01 |
| 2 | Denil Nanji Shekhat | Director | 22,378 | $11.9K | $0 | 5 | 2026-06-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MIRA Board & Officers
As of SEC filings through Jun 15, 2026Directors 5
- Erez Aminov · since Aug 2, 2023
- Denil Nanji Shekhat · since Mar 13, 2024
- Edward Clouston MacPherson · since Mar 13, 2024
- Matthew Paul Del Giudice · since Mar 13, 2024
- Matthew Pratt Whalen · since Nov 18, 2024
Officers 2
- Erez Aminov · Chief Executive Officer · since Aug 2, 2023
- Andriy Mushak · Chief Financial Officer · since Jun 2, 2026
Changes in the last 10 years (33)
| Jun 2, 2026 | The company announced the departure of Alan Weichselbaum as Chief Financial Officer in an SEC filing |
| Jun 2, 2026 | Andriy Mushak became Chief Financial Officer |
| May 15, 2025 | Alan Weichselbaum became Chief Financial Officer |
| Nov 18, 2024 | The company announced the departure of Michael Allen Jerman from the board in an SEC filing |
| Nov 18, 2024 | Matthew Pratt Whalen became a director |
| Mar 27, 2024 | Michelle Yanez listed as Chief Financial Officer (previously CFO, Secretary & Treasurer) in SEC filings |
| Mar 13, 2024 | The company announced the departure of Christopher C Chapman JR as Executive Chairman in an SEC filing |
| Mar 13, 2024 | The company announced the departure of Adam Kaplin as Pres. & Chief Scientific Off. in an SEC filing |
| Mar 13, 2024 | Matthew Paul Del Giudice became a director |
| Mar 13, 2024 | Edward Clouston MacPherson became a director |
| Mar 13, 2024 | Denil Nanji Shekhat became a director |
| Mar 9, 2024 | The company announced the departure of Talhia Tuck from the board in an SEC filing |
| Mar 9, 2024 | The company announced the departure of Hugh McColl III from the board in an SEC filing |
| Mar 9, 2024 | The company announced the departure of Bradley Kroenig from the board in an SEC filing |
| Jan 15, 2024 | The company announced the departure of Christos Nicholoudis from the board in an SEC filing |
| Dec 1, 2023 | The company announced the departure of Brian Frederick Daly from the board in an SEC filing |
| Nov 14, 2023 | Michael Allen Jerman became a director |
| Oct 25, 2023 | Brian Frederick Daly became a director |
| Oct 19, 2023 | The company announced the departure of David C Vorhoff from the board in an SEC filing |
| Sep 26, 2023 | Brian Patrick McNulty became a 10% owner |
| Aug 2, 2023 | Talhia Tuck became a director |
| Aug 2, 2023 | Michelle Yanez became CFO, Secretary & Treasurer |
| Aug 2, 2023 | Hugh McColl III became a director |
| Aug 2, 2023 | George Cappy became a 10% owner |
| Aug 2, 2023 | Erez Aminov became a director |
| Aug 2, 2023 | Erez Aminov became Chief Executive Officer |
| Aug 2, 2023 | David C Vorhoff became a director |
| Aug 2, 2023 | Christos Nicholoudis became a director |
| Aug 2, 2023 | Christopher C Chapman JR became a director |
| Aug 2, 2023 | Christopher C Chapman JR became Executive Chairman |
| Aug 2, 2023 | Bradley Kroenig became a director |
| Aug 2, 2023 | Bay Shore Trust became a 10% owner |
| Aug 2, 2023 | Adam Kaplin became Pres. & Chief Scientific Off. |
Not reported recently (5)
- Michelle Yanez · Last reported as Chief Financial Officer in an SEC filing dated Dec 10, 2024
- Bay Shore Trust · Last reported as a 10% owner in an SEC filing dated Aug 30, 2024
- Brian Patrick McNulty · Last reported as a 10% owner in an SEC filing dated Aug 30, 2024
- George Cappy · Last reported as a 10% owner in an SEC filing dated Aug 24, 2023
- Christopher C Chapman JR · Last reported as a director in an SEC filing dated Aug 21, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MIRA Proposed Insider Sales (Form 144)
Latest: 2024-11-19
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-11-19 | Erez Aminov | Affiliate | 100,000 | $141.0K | 2024-11-19 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2024-09-06 144/A | Brian McNulty | affiliate | 10,000 | $18.0K | 2024-09-04 | Alexander Capital LP | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
3 ETFs hold MIRA
3 shown · $690.92K total exposure · 0.00% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.